SANTA MONICA, Calif.--(BUSINESS WIRE)--
Kite Pharma, Inc. (Nasdaq:KITE) today announced that two of its key
advisors and scientific collaborators, both pioneers in the field of
cancer immunotherapy, have received the renowned Novartis Prize for
The winners were selected by an independent jury of seven world-class
immunologists for their groundbreaking research into the biology of the
Steven A. Rosenberg, M.D., Ph.D., Chief of Surgery at the National
Cancer Institute (NCI), and special advisor to Kite, Zelig Eshhar,
Ph.D., Professor emeritus from the Weizmann Institute of Science and
member of Kite's scientific advisory board, along with Carl June, M.D.
of the Perelman School of Medicine at the University of Pennsylvania,
have been recognized for their work on the pre-clinical and clinical
development, as well as the technological application of cellular immune
therapy using chimeric antigen receptor (CAR) T cells for diseases such
"We want to congratulate these three esteemed visionaries for their
contributions in advancing the field of cellular immunotherapy and for
bringing us closer to helping patients with no other options achieve
responses that may lead to a cure," said Arie Belldegrun, M.D., FACS,
Chairman, President and Chief Executive Officer of Kite. "We are proud
to partner with Dr. Rosenberg and Professor Eshhar in our ongoing
efforts to transform the treatment of cancer."
The Novartis Prizes for Immunology will be presented at the upcoming 16th International
Congress of Immunology (ICI) in Melbourne, Australia on August 22, 2016.
These prizes are awarded every three years for breakthrough
contributions to the fields of basic and clinical immunology.
About Kite Pharma
Kite Pharma, Inc., is a clinical-stage biopharmaceutical company engaged
in the development of novel cancer immunotherapy products, with a
primary focus on engineered autologous cell therapy (eACT™) designed to
restore the immune system's ability to recognize and eradicate tumors.
Kite is based in Santa Monica, CA. For more information on Kite Pharma,
please visit www.kitepharma.com.
Sign up to follow @KitePharma on Twitter at www.twitter.com/kitepharma.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160819005090/en/
Kite Pharma, Inc.
VP, Investor Relations
David Polk, 310-309-1029
Source: Kite Pharma, Inc.
News Provided by Acquire Media